CAR-T cell therapy for relapsed B-cell blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have B-cell acute lymphoblastic leukemia or certain types of B-cell non-Hodgkin lymphoma that has relapsed or not responded to treatment.
- Your cancer cells have the CD19 protein on their surface.
- You have signs of active disease, like a certain amount of cancer cells in bone marrow or a measurable tumor.
- Your liver, kidney, and heart function are within acceptable limits, and you have no active serious infections.
- You have never received CAR-T or other gene-modified cell therapy in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on leukemia cells. It's designed for people with relapsed or refractory B-cell acute lymphoblastic leukemia (a type of blood cancer) that hasn't responded to standard treatments.
This trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell blood cancers that have come back or not responded to treatment, and aims to see if this therapy can help control the cancer.
This trial tests a new type of immunotherapy called CAR-T cell therapy that targets a protein (CD19) on cancer cells. It is for people with B-cell leukemia or lymphoma that has not responded to standard treatment or has come back, and the goal is to help their immune system fight the cancer.
Hear when a new Acute Lymphoblastic Leukemia,B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.